Telyuk Pyotr, Hancock Helen, Maier Rebecca, Batty Jonathan A, Goodwin Andrew, Owens W Andrew, Ogundimu Emmanuel, Akowuah Enoch
Department of Cardiology, The James Cook University Hospital, Middlesbrough, UK.
Newcastle Clinical Trials Unit, Newcastle upon Tyne, UK.
Eur J Cardiothorac Surg. 2022 Dec 2;63(1). doi: 10.1093/ejcts/ezac540.
Aortic valve replacement (AVR) for severe symptomatic aortic stenosis is one of the most common cardiac surgical procedures with excellent long-term outcomes. Multiple previous studies have compared short-term outcomes of AVR with mini-sternotomy versus AVR with conventional sternotomy. We have previously reported the results of the randomized MAVRIC trial, which aimed to evaluate early postoperative morbidity among patients undergoing mini-sternotomy and conventional sternotomy AVR. We now report the long-term all-cause mortality, reoperation, MACE outcomes and echocardiographic data from this trial.
The prospective, randomized, single-centre, single-blind MAVRIC (manubrium-limited mini-sternotomy versus conventional sternotomy for aortic valve replacement) trial compared manubrium-limited mini-sternotomy and conventional median sternotomy for the treatment of patients with severe aortic stenosis. The previously reported primary outcome was the proportion of patients receiving red cell transfusion postoperatively and within 7 days of the index procedure. Currently reported exploratory analyses of a combined long-term all-cause mortality and reoperation were compared between groups via the log-rank test. Sensitivity analyses reviewed individual components of the combined end point. The primary analysis and long-term exploratory analyses were based on an intention-to-treat principle.
Between March 2014 and June 2016, 270 patients were enrolled and randomized in a 1:1 fashion to undergo mini-sternotomy AVR (n = 135) or conventional median sternotomy AVR (n = 135). At the median follow-up of 6.1 years, the composite outcome of all-cause mortality and reoperation occurred in 18.5% (25/135) of patients in the conventional sternotomy group and in 17% (23/135) of patients in the mini-sternotomy group. The incidence of chronic kidney disease, cerebrovascular accident and myocardial infarction was not significantly different between 2 groups. Follow-up echocardiographic data suggested no difference in peak and mean gradients or incidence of aortic regurgitation between 2 approaches.
This exploratory long-term analysis demonstrated that, in patients with severe aortic stenosis undergoing isolated AVR, there was no significant difference between manubrium-limited mini-sternotomy and conventional sternotomy with respect to all-cause mortality, rate of reoperation, MACE events and echocardiographic data at the median of 6.1-year follow-up.
对于重度有症状的主动脉瓣狭窄患者,主动脉瓣置换术(AVR)是最常见的心脏外科手术之一,具有出色的长期疗效。此前已有多项研究比较了采用微创胸骨切开术与传统胸骨切开术进行AVR的短期疗效。我们之前报告了随机MAVRIC试验的结果,该试验旨在评估接受微创胸骨切开术和传统胸骨切开术AVR患者术后早期的发病率。我们现在报告该试验的长期全因死亡率、再次手术、主要不良心血管事件(MACE)结局及超声心动图数据。
前瞻性、随机、单中心、单盲的MAVRIC(用于主动脉瓣置换的胸骨柄受限微创胸骨切开术与传统胸骨切开术)试验比较了胸骨柄受限微创胸骨切开术和传统正中胸骨切开术治疗重度主动脉瓣狭窄患者的效果。之前报告的主要结局是在索引手术术后7天内接受红细胞输血的患者比例。目前报告的对全因死亡率和再次手术合并的长期探索性分析通过对数秩检验在组间进行比较。敏感性分析评估了合并终点的各个组成部分。主要分析和长期探索性分析均基于意向性治疗原则。
2014年3月至2016年6月期间,270例患者入组并按1:1随机分组,分别接受微创胸骨切开术AVR(n = 135)或传统正中胸骨切开术AVR(n = 135)。在中位随访6.1年时,传统胸骨切开术组18.5%(25/135)的患者以及微创胸骨切开术组17%(23/135)的患者发生了全因死亡率和再次手术的复合结局。两组间慢性肾病、脑血管意外和心肌梗死的发生率无显著差异。随访超声心动图数据显示,两种手术方式在峰值和平均压力阶差或主动脉瓣反流发生率方面无差异。
这项探索性长期分析表明,在接受单纯AVR的重度主动脉瓣狭窄患者中,在中位6.1年随访时,胸骨柄受限微创胸骨切开术与传统胸骨切开术在全因死亡率、再次手术率、MACE事件及超声心动图数据方面无显著差异。